About the project
About the disease
EKC (epidemic keratoconjunctivitis) is a serious and contagious eye infection caused by mainly adenovirus type 8, 19 and 37. Symptoms include inflammation in the conjunctiva (conjunctivitis) and the cornea (keratitis), severe pain, edema and diminished eyesight, tearing, sensitivity to light. Due to the symptoms, the patients are unable to attend work or school, why many working hours are lost every year as a consequence of the disease. The costs to society in terms of both health care and lost of production are thus very substantial. Also, EKC may have long term implications for the patient’s eye sight.
On a global basis millions of patients are suffering of EKC every year. External ocular infections caused by adenoviruses are among the most common eye infections worldwide. Studies have shown that up to 65 percent of all conjunctivitis cases are viral and as many as 90 percent may be adenovirus and can cause considerable morbidity if not treated accordingly. Ocular adenoviral infection represents a significant health problem and there is a high medical need for an effective treatment. Currently, there is no specific anti-viral medicine available to shorten the course of infection, to improve the clinical symptoms, or to prevent the disease.
About the product
Adenovir Pharma is developing a topical antiviral pharmaceutical product for treatment of EKC, by preventing adenoviruses from binding to the receptors in the human eye. The product – eye drops – acts outside the human cells which should reduce the risk of developing viral resistance.
Our drug candidate APD-209 Eyedrops is concluded to be safe and well tolerated in several pre-clinical toxicity studies. A multi-center randomised double-masked placebo-controlled phase II clinical study in EKC patients has been completed. Clinical studies have showed that the product is safe and well tolerated. Interested in our compound, please contact us for further information.